Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SynthEtic LEthal Cancer Therapy in Mesothelioma (SELECTmeso): a Molecularly Stratified Multi-arm Phase II Platform Trial for Patients With Relapsed Malignant Mesothelioma Candidate Specific Trial: SELECTmeso1 A Phase II Trial of BMS-986504 in Patients With MTAP-deficient Relapsed Mesothelioma

NCT07602946 is registered in ClinicalTrials.gov with University of Southampton as lead sponsor.

NCT NCT07602946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07602946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SynthEtic LEthal Cancer Therapy in Mesothelioma (SELECTmeso): a Molecularly Stratified Multi-arm Phase II Platform Trial for Patients With Relapsed Malignant Mesothelioma Candidate Specific Trial: SELECTmeso1 A Phase II Trial of BMS-986504 in Patients With MTAP-deficient Relapsed Mesothelioma
Lead sponsor
University of Southampton
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 11, 2026
Completion date
August 31, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mesothelioma